<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="455">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04403607</url>
  </required_header>
  <id_info>
    <org_study_id>GN20ID164</org_study_id>
    <nct_id>NCT04403607</nct_id>
  </id_info>
  <brief_title>Cardiac Imaging in SARS-CoV-2 (COVID-19)</brief_title>
  <acronym>CISCO-19</acronym>
  <official_title>Cardiovascular and Pulmonary Imaging in SARS-CoV-2: A Study of the Heart, Lungs and Wellbeing After COVID-19.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Greater Glasgow and Clyde</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One-in-four patients with COVID-19 pneumonia develop life-threatening heart problems. Through
      cardiovascular imaging and biomarkers analyses this study aims to evaluate whether COVID-19
      infection results in heart injury. The investigators will also investigate which patients are
      at risk of heart injury as a result of COVID-19 and why only some patients suffer heart
      problems as a consequence of the infection. The study will also assess multisystem
      involvement including the lungs and kidneys.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study is supported through the Chief Scientist Office Rapid Research in Covid-19
      (RARC-19) programme. Our study will clarify the pathogenesis of cardiopulmonary injury,
      notably endotypes of myocardial injury including myocarditis, in patients with COVID-19.

      The study involves a prospective, observational, multicentre, longitudinal cohort design.The
      investigators aim to minimise selection bias by adopting consecutive screening of all-comers
      hospitalised with COVID-19 and the eligibility criteria are broad. For example, severe renal
      dysfunction is not an exclusion criterion. The sample size is 180 patients enrolled at
      baseline with 160 attending for the primary outcome evaluation (cardiac imaging) at 28 days
      post-discharge. The investigators will use advanced cardiovascular imaging to identify the
      number (proportion) of patients with myocardial inflammation (myocarditis) that is
      sub-clinical (i.e. not diagnosed) or clinically overt. Cardiovascular MRI and CT coronary
      angiography will provide a comprehensive examination one month after discharge is intended to
      detect persisting cardiovascular complications and diagnose clinical endotypes. The
      investigators aim to clarify the pathological significance of serial changes in circulating
      troponin, NTproBNP and renal function. By correlating the MRI findings with troponin I and
      other measures of cardiovascular injury, such as NTproBNP, our results will inform care
      pathways that use these blood tests to guide the management of patients with COVID-19.
      Correlation of imaging findings with baseline clinical information, biomarkers, patient
      reported outcome measures and well-being in the longer term will help to clarify the clinical
      significance of cardiovascular complications in COVID-19. Since the design is observational,
      an interim analysis may be undertaken with the timing informed by the enrolment rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary cardiac outcome is the proportion of patients with a diagnosis of myocardial inflammation (myocarditis).</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Myocardial inflammation (or myocarditis) will be revealed by cardiovascular magnetic resonance imaging (MRI) according to contemporary guidelines including the modified Lake Louise Criteria. The endotypes of myocardial injury are 1) myocardial inflammation due to 1.1) viral myocarditis, 1.2) ischaemia, or 1.3) stress (Takotsubo) cardiomyopathy, 2) myocardial infarction, 3) indeterminate, or 4) none. The final diagnosis will be a consensus-based determination by an expert panel. This information will provide insights into the incidence, nature, time-course and clinical significance of cardiovascular involvement in patients with COVID-19. The clinical significance of our findings will be assessed through associations with patient reported outcome measures (PROMS) and health outcomes in the longer term.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary cardio-pulmonary outcome is the proportion of patients with thrombosis</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Thrombosis of the right heart, pulmonary arteries and left heart will be determined contrast-enhanced CT chest, angiography and MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial injury</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Assess mechanisms using circulating biomarkers of cardiac injury, high sensitivity troponin I (ng/L) and its change over time from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial stress</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Assess the significance of myocardial injury by measuring circulating concentrations of NTproBNP (pg/mL) and its change over time from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic inflammation</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Assess systemic inflammation by measurement of the peak circulating concentration of C-reactive protein (mg/dL) and its change over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular injury</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Assess vascular injury/inflammation by measurement of the peak circulating concentration of IL-6 (pg/mL) and its change over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial activation and haemostasis</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Assess endothelial injury by immunoassay measurement of the peak circulating concentration of VWF:ag (IU/dL) and its change over time. Other measures of haemostasis will also be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin lysis</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Assess fibrin lysis by measurement of the peak circulating concentration of fibrin D-dimer (IU/dL) and its change over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Assess coagulation by measurement of Activated Partial Thromboplastin Time (APTT) in seconds. Other measures of coagulation will also be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Assess platelet count (n/microlitre), minimum value (thrombocytopaenia) and change over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Assess renal function using urine albumin:creatinine ratio and its change over time. Other measures of renal function/injury will also be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantify myocardial perfusion as a measure of coronary microvascular function</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Stress perfusion MRI will provide quantitative assessments of myocardial perfusion (ml/min/g) and classify perfusion abnormalities according to other MRI findings e.g. scar, inflammation and coronary artery disease as revealed by CT coronary angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of the primary outcome according to a prior history of cardiovascular disease or no history of prior cardiovascular disease.</measure>
    <time_frame>28 days after discharge from hospital</time_frame>
    <description>Imaging for coronary disease, PTE and lung pathology will be correlated with NHS clinical data on prior history of cardiovascular disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome measures (PROMS) - health status</measure>
    <time_frame>1 year</time_frame>
    <description>Health status, well being and function will be prospectively assessed using prespecified PROMS : EuroQOL EQ-5D-5L score. Other measures of health status will also be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMS - functional capacity</measure>
    <time_frame>1 year</time_frame>
    <description>Patient reported functional activity using the Duke Activity Status Index (DASI), measured by the score generated from the questionnaire (https://www.mdcalc.com/duke-activity-status-index-dasi)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cardiovascular science - vascular biology</measure>
    <time_frame>1 year</time_frame>
    <description>Exploratory study to help better understand the cardiovascular pathophysiology of COVID-19. The outcome is endothelial function in of isolated arterioles from gluteal biopsy. Endothelial function will be the (Emax, % vasorelaxation to acetylcholine in a pre-constricted arteriole). Other measures of vascular function will also be assessed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiovascular science - mathematical modelling</measure>
    <time_frame>1 year</time_frame>
    <description>Exploratory study to help better understand the cardiac biomechanical implications of COVID-19. The outcome measure will be myocardial stiffness (Cauchy stress, kPa). The sub-studies will involve using mathematical modelling and, relatedly, statistical emulation. The models will also include the coronary/pulmonary circulation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiovascular science - pathology</measure>
    <time_frame>1 year</time_frame>
    <description>The pathogenesis of SARS-CoV-2 will be examined using histopathology techniques. The outcome is SARS-CoV-2 viral protein or RNA identified in cardiovascular cells.</description>
  </other_outcome>
  <other_outcome>
    <measure>Health outcomes (serious adverse events)</measure>
    <time_frame>20 years</time_frame>
    <description>Health outcomes as measured by the occurrence of serious adverse events (SAE) quantified by 1) rehospitalisation and 2) death. These events will be identified in the longer term using electronic record linkage to health records held by government and the National Health Service.</description>
  </other_outcome>
  <enrollment type="Anticipated">180</enrollment>
  <condition>COVID</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples will be stored for biomarker analyses including DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All-comers who have attended or admitted to hospital for COVID-19 and meet the eligibility
        criteria described
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of hospital attendance or hospitalisation for COVID-19, confirmed by a
             clinical diagnosis, laboratory test e.g. PCR and/or a radiological test e.g. CT chest
             or chest X-ray

          -  Age 18 years or more

          -  Capacity to provide written informed consent

          -  Able to comply with study procedures

        Exclusion Criteria:

          -  Contra-indication to CMR e.g. severe claustrophobia, metallic foreign body

          -  Lack of informed consent

          -  Women who are pregnant, breast-feeding or of child-bearing potential without a
             negative pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Berry, MBChB/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow / NHS Greater Glasgow &amp; Clyde</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colin Berry, MBChB/PhD</last_name>
    <phone>01413303325</phone>
    <email>colin.berry@glasgow.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kenneth Mangion, MBChB/PhD</last_name>
    <email>kenneth.mangion@glasgow.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Paisley</city>
        <state>Renfrewshire</state>
        <zip>PA2 9PJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynsey Gillespie, PhD</last_name>
      <phone>+44 (141) 887 9111</phone>
      <email>Glasgow.CRF@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Douglas Grieve, MBChB/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynsey Gillespie, PhD</last_name>
      <phone>+44 (141) 211 6800</phone>
      <email>Glasgow.CRF@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Hannah Bayes, MBChB/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynsey Gillespie, PhD</last_name>
      <phone>+44 (0141) 232 7600</phone>
      <email>Glasgow.CRF@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Kevin Blyth, MBChB/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.glasgowctu.org/Home</url>
    <description>Glasgow Clinical Trials Unit</description>
  </link>
  <link>
    <url>https://www.cso.scot.nhs.uk/covidcalloutcome/</url>
    <description>Chief Scientist Office, Scottish Government - Rapid Research in Covid-19 (RARC-19)</description>
  </link>
  <link>
    <url>https://www.gla.ac.uk/researchinstitutes/icams/research/bhfcoeglasgow/</url>
    <description>British Heart Foundation Centre of Research Excellence</description>
  </link>
  <reference>
    <citation>Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, Madhur MS, Tomaszewski M, Maffia P, D'Acquisto F, Nicklin SA, Marian AJ, Nosalski R, Murray EC, Guzik B, Berry C, Touyz RM, Kreutz R, Wang DW, Bhella D, Sagliocco O, Crea F, Thomson EC, McInnes IB. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020 Aug 1;116(10):1666-1687. doi: 10.1093/cvr/cvaa106.</citation>
    <PMID>32352535</PMID>
  </reference>
  <reference>
    <citation>Cosyns B, Lochy S, Luchian ML, Gimelli A, Pontone G, Allard SD, de Mey J, Rosseel P, Dweck M, Petersen SE, Edvardsen T. The role of cardiovascular imaging for myocardial injury in hospitalized COVID-19 patients. Eur Heart J Cardiovasc Imaging. 2020 Jul 1;21(7):709-714. doi: 10.1093/ehjci/jeaa136. Review.</citation>
    <PMID>32391912</PMID>
  </reference>
  <reference>
    <citation>Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heli√∂ T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d. doi: 10.1093/eurheartj/eht210. Epub 2013 Jul 3.</citation>
    <PMID>23824828</PMID>
  </reference>
  <reference>
    <citation>Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176. doi: 10.1016/j.jacc.2018.09.072. Review.</citation>
    <PMID>30545455</PMID>
  </reference>
  <reference>
    <citation>Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018 Nov 13;138(20):e618-e651. doi: 10.1161/CIR.0000000000000617. Erratum in: Circulation. 2018 Nov 13;138(20):e652.</citation>
    <PMID>30571511</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

